Table 1 Multivariate analysis for overall and disease-free survivala

From: Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis’

 

Overall survival

Disease-free survival

Variables

HR (95% CI)

P value

HR (95% CI)

P value

CEBPA single-mut

1.614 (0.743–3.508)

0.227

1.164 (0.630–2.149)

0.629

CEBPA double-mut

0.362 (0.182–0.721)

0.004

0.426 (0.263–0.691)

0.001

Karyotype

2.388 (1.774–3.215)

<0.001

2.387 (1.899–3.002)

<0.001

Ageb

2.741 (1.959–3.836)

<0.001

1.488 (1.137–1.948)

0.004

Sexc

0.937 (0.670–1.311)

0.704

1.107 (0.848–1.445)

0.456

WBCd

1.524 (1.051–2,209)

0.026

1.396 (1.031–1.890)

0.031

FLT3/ITD

1.798 (1.232–2.624)

0.002

1.843 (1.350–2.515)

<0.001

AML1/RUNX1

1.755 (1.036–2.972)

0.036

1.410 (0.909–2.187)

0.125

NPM1

0.500 (0.317–0.789)

0.003

0.482 (0.332–0.699)

<0.001

  1. Abbreviations: CI=confidence interval; HR=hazard ratio.
  2. aIncluding 397 patients who received standard chemotherapy. Those patients who did not receive chemotherapy or only low dose chemotherapy were excluded.
  3. bAge greater than 50-years old vs less than 50-years old.
  4. cMale vs female.
  5. dWBC greater than 50 × 109/l vs less than 50 × 109/l.
Back to article page